Drugs / ORTD-1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04286789 | Mar → Oct 2021 | rheumatoid arthritis | Oryn Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04708236 | Apr → May 2021 | COVID-19 | Oryn Therapeutics, LLC | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORTD-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04708236 ↗ |
| Route | Subcutaneous | “Once weekly, single subcutaneous injection of ORTD-1 at a volume of 0.45 mL.” NCT04286789 ↗ |